CSL Behring Medical Expert Portal is a European webpage designed for healthcare professionals (HCPs) who are interested in serious and life-threatening conditions. Register and login to access the information on this webpage and to receive updates when new content becomes available. If you are interested in the relevant content for a specific country, please refer to the CSL Behring affiliate in your country to obtain relevant information. The medical and scientific information provided on this website is for informational purposes only and should not replace professional advice from a healthcare provider in your area. It is important that you always adhere to the regulations and guidelines relevant to your country.

Disclaimer: Due to compliance regulations, not all content of this webpage is intended for UK healthcare practitioners. If you would like to access UK specific materials on this site, please reach out to your local CSL Behring medical representative (medinfo@cslbehring.com) for assistance.

Disclaimer

Patient cases

Comorbidities in CIDP

Case provided by Prof. Gwendal Le Masson

 

KEY TAKEAWAYS

  • Adjusting the IVIG dose to patients with CIDP and obesity must be done with caution and with individual assessment of clinical outcomes1
  • The IVIG wear-off effects observed in this patient with obesity were overcome by switching the patient to SCIG for maintenance treatment
  • SCIG, possibly by allowing more frequent injections and steadier Ig concentration,2 could help manage IVIG wear-off effects; further studies are required to confirm this effect3